Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 6 | Vintage Vibes

Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit

Comments by former professor of medicine at Oxford follow scrapping of planned London research centre

The Guardian - UK

Humiliation For Britain: US Pharma Giant Merck Axes £1 Billion London Lab, Brands UK 'Uninvestable'

Humiliation For Britain: US Pharma Giant Merck Axes £1 Billion London Lab, Brands UK 'Uninvestable'

Merck scraps £1B London research centre, branding UK 'uninvestable' due to NHS pricing and low investment. 125 jobs lost, threatening Britain's life sciences goals

International Business Times UK

Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’

Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’

UK pharmaceutical sector ‘risks losing investment to other countries’.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

The Guardian - UK

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck Co. Inc.’s (NYSE:MRK) anti-PD-1 therapy Keytruda (pembrolizumab), for the first-line treatment of unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation…

This Merck Pill Promises Powerful Cholesterol Reduction Without Injections

Merck Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).

Is Merck Stock Outperforming the Dow?

As Merck has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

RFK Jr.'s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement

RFK Jr.'s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement

Health Secretary Robert F

The Independent UK

Is Wall Street Bullish or Bearish on Merck Stock?

Is Wall Street Bullish or Bearish on Merck Stock?

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

1 Blue-Chip Dividend Stock That Still Has Room to Run

1 Blue-Chip Dividend Stock That Still Has Room to Run

This pharmaceutical leaders offers a combination of growth, income, and innovation.

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Get all your
news in one place.

100's of premium titles.
One news app.

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:GSK) on Monday to develop up to 12 medicines.

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

Merck Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29.

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

Stocks Settle Higher on Tech Stock Strength and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.72%. September E-mini S&P futures (ESU25 ) are up +0.57%, and September E-mini Nasdaq futures...

Get all your
news in one place.

100's of premium titles.
One news app.

Stocks Climb on Strength in the Magnificent Seven Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.28%. September E-mini S&P futures (ESU25 ) are up +0.22%, and September E-mini Nasdaq futures...

What You Need To Know Ahead of Merck's Earnings Release

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Stocks See Support as Investors Await Tariff News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.66%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.83%. September E-mini S&P futures (ESU25 ) are up +0.56%, and September E-mini Nasdaq futures...

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.

The Guardian - US

First meeting of new CDC vaccine panel reveals policy chaos sown by RFK Jr

Health secretary unilaterally appointed ACIP’s eight new members, several of whom are critical of immunizations

Merck exec says Chernobyl changed the course of her life after her father begged her to leave nuclear physics on his deathbed

Gen Z grads are slamming degrees as worthless—but Fortune 500 boss, Doina Ionescu, says her MBA was the best investment because ‘it has fundamentally changed me as a person’.

Could the answers to cancer lie in space? Why off-Earth research is heating up

The space environment is not kind to human bodies. The final frontier may therefore be the perfect place to study cancer — and someday even treat it.

1 … 5 6 7 8

People

212,077 stories

Robert F. Kennedy Jr

Martin Kulldorff

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,876 stories

148,742 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play